Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ: SMMT )

18.50 +0.51 (+2.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
From Summit Therapeutics Inc.
Via Business Wire
Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development
From Summit Therapeutics Inc.
Via Business Wire
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
Ivonescimab’s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023
From Summit Therapeutics Inc.
Via Business Wire
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Acurx Pharmaceuticals Share Price And Volume Are Surging Ahead Of Phase 2b Trial Data Release ($ACXP)
Via AB Newswire
Topics Death
Exposures Death
Summit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023
From Summit Therapeutics Inc.
Via Business Wire
H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development
From Summit Therapeutics Inc.
Via Business Wire
Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc. 
Via Benzinga
Wyndham Hotels & Resorts, Olink Holding And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 50 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer
From Summit Therapeutics Inc.
Via Business Wire
5 Meme Stocks to Sell Immediately, According to AI
As we move into September, the MarketMaster AI is flashing warning signals about risky equities. Sell these meme stocks right now. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal
Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for a novel anti-inflammatory to One Bio of Florida in a $1 billion deal. One Bio will make an $21.5 million payment upfront along with a... 
Via Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration... 
Via Benzinga
Cleveland-Cliffs, United States Steel, monday.com And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Nasdaq Composite gaining around 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023
From Summit Therapeutics Inc.
Via Business Wire
AlloVir, DigitalOcean And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. AlloVir, Inc. (NASDAQ: ALVR) shares dipped 24.1% to $3.74 in pre-market... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023
From Summit Therapeutics Inc.
Via Business Wire
Ivonescimab Updated Data to be Featured at ASCO 2023
From Summit Therapeutics Inc.
Via Business Wire
Why Shares of Summit Therapeutics Slumped on Tuesday
The company's shares have been falling since it announced earnings late last week. 
Via The Motley Fool
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture recently announced an $11.55 million registered direct offering. 
Via Benzinga
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)
From Summit Therapeutics Inc.
Via Business Wire
Why Shares of Summit Therapeutics Soared This Week
Summit Therapeutics advanced its lead therapy into two phase 3 trials to treat non-small cell lung cancer. 
Via The Motley Fool
Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)
From Summit Therapeutics Inc.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
From Schall Law Firm
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.